Navigation Links
AEterna Zentaris to Announce First Quarter 2009 Financial and Operating Results and Hold Annual Shareholder Meeting on May 6, 2009
Date:4/30/2009

QUEBEC CITY, April 30 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, will announce its first quarter 2009 financial and operating results before market open on Wednesday, May 6, 2009. The Company will host a conference call and webcast to discuss these results later that same day at 3:30 p.m., Eastern Time.

Participants may access the live webcast via the Company's website at www.aezsinc.com in the "Investors" section, or by telephone using the following numbers: 416-644-3422, 514-807-8791 or 800-587-1893. A replay of the webcast will also be available on the Company's website for a period of 30 days.

The Company further announced that it will hold its Annual Shareholder Meeting also on Wednesday, May 6, 2009 starting at 10:30 a.m. Eastern Time, in Rooms 6 and 7 of the Centre Sheraton Montreal Hotel, 1201 Rene-Levesque Boulevard West, in Montreal.

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology with proven expertise in drug discovery, development and commercialization. News releases and additional information are available at www.aezsinc.com.


'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. AEterna Zentaris Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement
2. AEterna Zentaris Presents Phase 1 Results for AEZS-112 in Patients with Advanced Cancer and Lymphoma at AACR Annual Meeting in Denver
3. AEterna Zentaris Presents Two Posters on its PI3K Inhibitor Compound, AEZS-126, at AACR Annual Meeting
4. AEterna Zentaris To Present Data on Anticancer Compounds AEZS-112 and AEZS-126 at AACR Annual Meeting
5. AEterna Zentaris Reports Fourth Quarter and Full-Year 2008 Financial and Operating Results
6. AEterna Zentaris to Announce Fourth Quarter and Full-Year 2008 Financial and Operating Results on March 11, 2009
7. AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia
8. AEterna Zentaris to Present at Upcoming RBC Capital Markets Healthcare Conference
9. AEterna Zentaris Closes Sale of Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
10. AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results
11. AEterna Zentaris to Announce Third Quarter 2008 Financial and Operating Results on November 13, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... MAYNARD, Mass. , Jan. 19, 2017 ... company focused on enhancing productivity in aquaculture and a ... ), announces that it has completed the listing of ... finalized the equity subscription from Intrexon. "AquaBounty,s ... Company that will broaden our exposure to the U.S. ...
(Date:1/19/2017)... ... 2017 , ... DaVita Clinical Research (DCR), a ... device development, and Prism Clinical Research , a leader in providing fully ... Clinical Trials (VCT) has been selected by both companies as an exclusive ...
(Date:1/19/2017)... BD (Becton, Dickinson and Company) (NYSE: BDX ), a ... live webcast of its Annual Meeting of Shareholders on Tuesday, January ... can be accessed from the BD corporate website at http://www.bd.com/investors/ ... ... BD is a global medical technology company that is ...
(Date:1/18/2017)... LINCOLN, Mass. , Jan. 18, 2017 /PRNewswire/ ... in applying mechanistic modeling to drug research and ... , PhD, Co-Founder, President, and CEO of Applied ... Group for Informatics and Modeling (BAGIM) Meeting on ... in Cambridge , MA.   Dr. ...
Breaking Biology Technology:
(Date:1/11/2017)... 2017 Intoxalock, a leading ignition interlock provider, ... its patent-pending calibration device. With this new technology, Intoxalock ... upload data logs and process repairs at service center ... "Fighting drunk driving through the application of cutting-edge technologies ... but also for the customer who can get back ...
(Date:1/6/2017)... , Jan. 6, 2017  Privately-held CalciMedica, ... studies in healthy volunteers of a novel calcium ... treat acute pancreatitis. Acute pancreatitis, ... a mild disorder, but can be very serious.  In ... and sepsis, where extended hospital stays, time in ...
(Date:1/6/2017)... 5, 2017  Delta ID Inc., a leader in ... for automotive at CESĀ® 2017. Delta ID has collaborated ... demonstrate the use of iris scanning as a secure, ... driver in a car, and as a way to ... Delta ID and Gentex will demonstrate (booth ...
Breaking Biology News(10 mins):